2.47 USD
-0.09
3.52%
At close May 14, 4:00 PM EDT
After hours
2.26
-0.21
8.50%
1 day
-3.52%
5 days
6.47%
1 month
7.39%
3 months
-42.69%
6 months
-33.96%
Year to date
-50.60%
1 year
-32.33%
5 years
-77.04%
10 years
-46.65%
 

About: Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Employees: 188

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

180% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

87% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 30

58% more capital invested

Capital invested by funds: $194M [Q3] → $306M (+$112M) [Q4]

15% more funds holding

Funds holding: 116 [Q3] → 133 (+17) [Q4]

9.9% less ownership

Funds ownership: 88.71% [Q3] → 78.81% (-9.9%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for CDXS.

Financial journalist opinion

Based on 6 articles about CDXS published over the past 30 days

Neutral
Seeking Alpha
4 hours ago
Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Georgia Erbez - Chief Financial Officer Stefan Lutz - Senior Vice President of Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Tycho Peterson - Jefferies Allison Bratzel - Piper Sandler Dan Arias - Stifel Matthew Hewitt - Craig-Hallum Brendan Smith - TD Cowen Operator Greetings and welcome to the Codexis First Quarter 2025 Earnings Conference Call and webcast. At this time, all participants are in a listen-only mode.
Codexis, Inc. (CDXS) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
5 hours ago
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.16 per share a year ago.
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
7 hours ago
Codexis Reports First Quarter 2025 Financial Results
Secured first revenue-generating contract for ECO Synthesis™ manufacturing services Company reiterates full-year financial guidance Six presentations to feature the ECO Synthesis platform at upcoming TIDES USA annual meeting, including three from leading CDMO collaborators REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced financial results for the first quarter ended March 31, 2025, and provided a business update.
Codexis Reports First Quarter 2025 Financial Results
Neutral
GlobeNewsWire
1 week ago
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
Neutral
GlobeNewsWire
2 weeks ago
Codexis to Report First Quarter 2025 Financial Results on May 14
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
Codexis to Report First Quarter 2025 Financial Results on May 14
Positive
Zacks Investment Research
2 weeks ago
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Codexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
Neutral
GlobeNewsWire
1 month ago
Codexis Announces Byron Dorgan to Retire from Board of Directors
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan will retire from the Company's Board of Directors when his current term ends at the 2025 Annual Meeting of Stockholders. Mr. Dorgan joined the Board in 2011, served as Chairman from 2021 through 2024, and currently serves as the Chair of the Nominating and Corporate Governance Committee. He will remain a consultant to Codexis for one year following his departure from the Board.
Codexis Announces Byron Dorgan to Retire from Board of Directors
Neutral
GlobeNewsWire
2 months ago
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the approval of equity grants to two new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 10,000 shares of Codexis common stock and (ii) 5,000 restricted stock units (RSUs) as inducement awards under the Company's 2024 Inducement Plan.
Codexis Announces New Employment Inducement Grants
Neutral
Seeking Alpha
2 months ago
Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Kevin Norrett - Chief Operating Officer Georgia Erbez - Chief Financial Officer Conference Call Participants Richard Miller - Cantor Fitzgerald, L.P. Matthew Stanton - Jefferies Group LLC Allison Bratzel - Piper Sandler Companies Dan Arias - Stifel Financial Corp. Jacob Johnson - Stephens Inc. Matthew Hewitt - Craig-Hallum Capital Group LLC Brendan Smith - TD Cowen Operator Welcome to the Codexis Fourth Quarter and Full Year 2024 Earnings Conference Call.
Codexis, Inc. (CDXS) Q4 2024 Earnings Call Transcript
Negative
Zacks Investment Research
2 months ago
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.02 per share a year ago.
Codexis (CDXS) Reports Q4 Loss, Misses Revenue Estimates
Charts implemented using Lightweight Charts™